Probiotics for people with hepatic encephalopathy

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 2, 2017, Pages

  Dalal, Rohan ^a   Mcgee, Richard G ^b   Riordan, Stephen M ^c   Webster, Angela C ^d  

^a WESTMEAD HOSPITAL   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^c Prince os Wales Private Hospital   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIA; LACTULOSE; PLACEBO; PROBIOTIC AGENT; GASTROINTESTINAL AGENT;

AMMONIA BLOOD LEVEL; DRUG EFFECT; DRUG HYPERSENSITIVITY; HEPATIC ENCEPHALOPATHY; HUMAN; LENGTH OF STAY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPSIS; SIDE EFFECT; SYSTEMATIC REVIEW; CAUSE OF DEATH; META ANALYSIS;

CAUSE OF DEATH; GASTROINTESTINAL AGENTS; HEPATIC ENCEPHALOPATHY; HUMANS; LACTULOSE; PROBIOTICS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85013782569     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008716.pub3     Document Type: Review

References (350)

1. Bajaj JS, Christensen KM, Hafeezullah M, Varma RR, Franco J, Hoffmann RG, et al. Randomized trial of probiotic yogurt in minimal hepatic encephalopathy - It helps to bug your patient. Digestive Disease Week 2007;132(4):A800. 3032185
2. Bajaj JS, Saeian K, Christensen KM, Hafeezullah M, Varma RR, Franco J, et al. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. American Journal of Gastroenterology 2008;103(7):1707-15. 3032186
3. McGee R. Request for clinical trial information [personal communication]. Email to: JS Bajaj 14 October 2010. 3032187
4. Bajaj JS, Heuman D, Hylemon P, Sanyal A, Sterling R, Stravitz R, et al. Systems biology analysis of probiotic lactobacillus GG in cirrhotic patients with minimal hepatic encephalopathy: a randomized double-blind, placebo-controlled trial. Journal of Hepatology 2014; Vol. 1:S221. [0168-8278]3032189
5. Bajaj JS, Heuman DM, Hylemon PB, Sanyal AJ, Puri P, Sterling RK, et al. Randomised clinical trial: lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Alimentary Pharmacology & Therapeutics 2014; Vol. 39, issue 10:1113-25. [0269-2813]3032190
6. Dhiman R, Khatri A, Rana S, Chopra M, Thumburu K, Malhotra S, et al. Probiotic preparation in the treatment of MHE - A double-blind, randomized, placebo controlled study. Journal of Gastroenterology and Hepatology 2013; Vol. 28:401-2. [0815-9319]3032192
7. Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology (Baltimore, Md.) 2004;39(5):1441-9. 3032194
8. Loguercio C, Del Vecchio Blanco C, Coltorti M. Enterococcus lactic acid bacteria strain SF68 and lactulose in hepatic encephalopathy: a controlled study. Journal of International Medical Research 1987;15(6):335-43. 3032196
9. McGee R. Request for clinical trial information [personal communication]. Email to: C Loguercio 15 October 2010. 3032197
10. Loguercio C, Abbiati R, Rinaldi M, Romano A, Del Vecchio Blanco C, Coltorti M. Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. Journal of Hepatology 1995; Vol. 23, issue 1:39-46. [0168-8278: (Print); ]3032199
11. Lunia MK, Sharma BC, Srivastav S, Sachdeva S. Efficacy of probiotics on minimal hepatic encephalopathy and improvement in small intestinal bacterial overgrowth and orocecal transit time in cirrhosis: a randomised controlled trial. Journal of Hepatology 2014; Vol. 1:S246. [0168-8278]3032201
12. Malaguarnera M, Gargante MP, Malaguarnera G, Salmeri M, Mastrojeni S, Rampello L, et al. Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy. European Journal of Gastroenterology & Hepatology 2010;22(2):199-206. 3032203
13. McGee R. Request for clinical trial information [personal communication]. Email to: BC Sharma 14 October 2010. 3032207
14. Mittal VV, Sharma BC, Sharma P, Sarin SK. A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. European Journal of Gastroenterology & Hepatology 2011; Vol. 23, issue 8:725-32. [0954-691X]3032205
15. Mittal VV, Sharma P, Sharma B, Sarin SK. Treatment of minimal hepatic encephalopathy: a randomized controlled trial comparing lactulose, probiotics and L-ornithine L-aspartate with placebo. Hepatology (Baltimore, Md.) 2009;4 (Suppl):471A. 3032206
16. Mouli VP, Benjamin J, Bhushan Singh M, Mani K, Garg SK, Saraya A, et al. Effect of probiotic VSL#3 in the treatment of minimal hepatic encephalopathy: a non-inferiority randomized controlled trial. Hepatology Research 2015; Vol. 45, issue 8:880-9. [1872-034X]3032209
17. Dalal R. Request for clinical trial information [personal communication]. Email to: RRS Nair 26 April 2015. 3032214
18. Nair RR. Early detection of hepatic encephalopathy in preclinical stage with evoked response studies: a randomised control trial. Neurology 2011; Vol. 76, issue 9:A222-3. [0028-3878]3032211
19. Nair RRS, Abdurahiman P, Jose J, Sebastian S, Thomas V, Girija A. Brainstem evoked response audiometry versus visual evoked response in detecting minimal hepatic encephalopathy and to assess the response after treatment with probiotics - A randomized double blind placebo controlled study. American Academy of Neurology 2008;70(11):A50. 3032212
20. Nair RRS, Jose J, Thomas V. BERA vs VEP in subclinical hepatic encephalopathy - A randomised control trial. Annals of Neurology 2009; Vol. 66:S28-9. [0364-5134]3032213
21. Pereg D, Kotliroff A, Gadoth N, Hadary R, Lishner M, Kitay-Cohen Y. Probiotics for patients with compensated liver cirrhosis: a double-blind placebo-controlled study. Nutrition 2011;27(2):177-81. 3032216
22. Qiao X-L. Clinical researches of bifid triple viable on the treatment of subclinical hepatic encephalopathy. Chinese Journal of Clinical Gastroenterology 2010; Vol. 22, issue 2:105-6. 3032218
23. Saji S, Kumar S, Thomas V. A randomized double blind placebo controlled trial of probiotics in minimal hepatic encephalopathy. Tropical Gastroenterology 2011; Vol. 32, issue 2:128-32. [0250-636X]3032220
24. McGee R. Request for clinical trial information [personal communication]. Email to: BC Sharma 14 October 2010. 3032222
25. Sharma P, Sharma BC, Puri V, Sarin SK. A randomized control trial of lactulose versus probiotics versus lactulose plus probiotics in the treatment of minimal hepatic encephalopathy of cirrhosis. 71st Annual Scientific Meeting of the American College of Gasroenterology, 2006 10 20-25, Las Vegas. American College of Gastroenterology, 2006; Vol. 101, issue 9:402. 3032223
26. Sharma P, Sharma BC, Puri V, Sarin SK. An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. European Journal of Gastroenterology & Hepatology 2008;20(6):506-11. 3032224
27. Pant S, Dwivedi M, Misra SP, Narang S, Sharma K. Minimal hepatic encephalopathy: effect of rifaximin, probiotics and L-ornithine L-aspartate. Indian Journal of Gastroenterology 2011; Vol. 1:A51. [0254-8860]3032226
28. Pant S, Sharma K, Misra SP, Dwivedi M, Narang S, Mishra K, et al. Effect of rifaximin, probiotics and L-ornithine L-aspartate on minimal hepatic encephalopathy: a case control study. Indian Journal of Gastroenterology 2013; Vol. 1:A92. [0254-8860]3032227
29. Sharma K, Pant S, Dwivedi M, Misra SP, Misra A, Narang S. Minimal hepatic encephalopathy: effect of rifaximin, probiotics and L-ornithine L-aspartate. Journal of Gastroenterology and Hepatology 2012; Vol. 27:275-6. [0815-9319]3032228
30. Sharma K, Pant S, Misra S, Dwivedi M, Misra A, Narang S, et al. Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial. Saudi Journal of Gastroenterology 2014; Vol. 20, issue 4:225-32. [1319-3767]3032229
31. Shavakhi A, Hashemi H, Tabesh E, Derakhshan Z, Farzamnia S, Meshkinfar S, et al. Multistrain probiotics and lactulose in the treatment of minimal hepatic encephalopathy. Journal of Research in Medical Sciences 2014; Vol. 19, issue 8:703-8. [1735-7136]3032231
32. Vlachogiannakos J, Vasianopoulou P, Via-zis N, Chroni M, Voulgaris T, Ladas SD, et al. The role of probiotics in the treatment of minimal hepatic encephalopathy. A prospective, randomized, placebo-controlled, double-blind study. Hepatology (Baltimore, Md.) 2014; Vol. 60, issue 4 Suppl:376A. 3032233
33. Vlachogiannakos J, Vasianopoulou P, Viazis N, Chroni M, Karamanolis D, Ladas SD. Reversal of minimal hepatic encephalopathy after a probiotic administration. A prospective, randomized, placebo-controlled, double-blind study. Journal of Hepatology 2016; Vol. 64, issue Suppl 2:S165. [1600-0641]5282287
34. Zhao X-H, Feng Q, Zhang J, Jiang Y-F. A randomized-controlled trial to compare the effect of lactulose and probiotics on treatment of minimal hepatic encephalopathy. Practical Journal of Clinical Medicine 2013; Vol. 10, issue 4:61-3. 3032235
35. Zhitai Z. Clinical application of probiotics in the treatment of hepatic encephalopathy. Journal of Gastroenterology and Hepatology 2013; Vol. 28:851. [0815-9319]3032237
36. Ziada DH, Soliman HH, Yamany SA, Hamisa MF, Hasan AM. Can Lactobacillus acidophilus improve minimal hepatic encephalopathy? A neurometabolite study using magnetic resonance spectroscopy. Arab Journal of Gastroenterology 2013; Vol. 14, issue 3:116-22. 3032239
37. Adams LA, Angulo P. Treatment of non-alcoholic fatty liver disease. Postgraduate Medical Journal 2006;82(967):315-22. 3032247
38. Agrawal M, Homel P, Badalov N, Mayer I, Rahmani R. Probiotics in minimal hepatic encephalopathy: a meta-analysis. American Journal of Gastroenterology 2012;107:S153-4. 3032251
39. Agrawal A, Sharma BC, Sharma P, Sarin SK. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open label, randomized controlled trial of lactulose, probiotics and no-therapy. Journal of Gastroenterology and Hepatology 2011; Vol. 26:7. [0815-9319]3032253
40. Agrawal A, Sharma BC, Sharma P, Sarin SK. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. American Journal of Gastroenterology 2012; Vol. 107, issue 7:1043-50. [0002-9270]3032254
41. Agrawal A, Sharma P, Sharma B, Sarin S. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open label, randomized controlled trial of lactulose, probiotics and no-therapy. American Journal of Gastroenterology 2010; Vol. 105:S105. [0002-9270]3032255
42. NCT01178372 . Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open label, randomized controlled trial of lactulose, probiotics and no-therapy. apps.who.int/trialsearch/Trial.aspx?TrialID=NCT01178372 first recieved August 9 2010. 3032256
43. Al Sibae MR, McGuire BM. Current trends in the treatment of hepatic encephalopathy. Therapeutics and Clinical Risk Management 2009;5(1):617-26. 3032260
44. Albillos A, de la Hera A. Multifactorial gut barrier failure in cirrhosis and bacterial translocation: working out the role of probiotics and antioxidants. Journal of Hepatology 2002;37(4):523-6. 3032262
45. Alisi A, Bedogni G, Baviera G, Giorgio V, Porro E, Paris C, et al. Randomised clinical trial: the beneficial effects of VSL# 3 in obese children with non-alcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics 2014; Vol. 39, issue 11:1276-85. [0269-2813]3032270
46. Aller R, De Luis DA, Izaola O, Conde R, Gonzalez Sagrado M, Primo D, et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. European Review for Medical and Pharmacological Sciences 2011; Vol. 15, issue 9:1090-5. 3032274
47. Almeida J, Galhenage S, Yu J, Kurtovic J, Riordan SM. Gut flora and bacterial translocation in chronic liver disease. World Journal of Gastroenterology 2006;12(10):1493-502. 3032276
48. Arya R, Gulati S, Deopujari S. Management of hepatic encephalopathy in children. Postgraduate Medical Journal 2010;86(1011):34-41. 3032282
49. Bai M, Yang Z, Qi X, Fan D, Han G. L-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials. Journal of Gastroenterology and Hepatology 2013;28:783-92. 3032292
50. Bajaj J. Minimal hepatic encephalopathy matters in daily life. World Journal of Gastroenterology 2008;14(23):3609-15. 3032296
51. Bajaj JS. Management options for minimal hepatic encephalopathy. Expert Review of Gastroenterology & Hepatology 2008;2(6):785-90. 3032298
52. Bajaj JS. Commentary: Probing probiotics in cirrhosis - A template for future studies? Author's reply. Alimentary Pharmacology & Therapeutics 2014;39:1335-6. 3032300
53. Barclay AR, Beattie LM, Weaver LT, Wilson DC. Systematic review: medical and nutritional interventions for the management of intestinal failure and its resultant complications in children. Alimentary Pharmacology & Therapeutics 2011;33(2):175-84. 3032306
54. Barreto-Zuniga R, Naito Y, Li ZI, Zhang D, Yoshioka M, Ideo GM, et al. Anti-endotoxin capacity and reticulo-endothelial function in alcohol-related liver cirrhosis: a randomized pilot study comparing a probiotic preparation versus lactulose. International Medical Journal 2001;8(2):101-7. 3032308
55. Bass NM. Emerging therapies for the management of hepatic encephalopathy. Seminars in Liver Disease 2007;27(Suppl 2):18-25. 3032310
56. Bengmark S. Bio-ecological control of chronic liver disease and encephalopathy. Metabolic Brain Disease 2009;24:223-36. 3032324
57. Bengmark S, Di Cocco P, Clemente K, Corona L, Angelico R, Manzia TM, et al. Bio-ecological control of chronic liver disease and encephalopathy. Minerva Medica 2011;102:309-19. 3032326
58. Bengmark S. Gut microbiota, immune development and function. Pharmacological Research 2013;69:87-113. 3032328
59. Bismuth M, Funakoshi N, Cadranel JF, Blanc P. Hepatic encephalopathy: from pathophysiology to therapeutic management. European Journal of Gastroenterology & Hepatology 2011;23(1):8-22. 3032338
60. Boca M, Vyskocil M, Mikulecky M, Ebringer L, Kolibas E, Kratochvil'ova H, et al. Complex therapy of chronic hepatic encephalopathy completed with probiotic: comparison of two studies [Komplexna liecba chronickej hepatalnej encefalopatie doplnena probiotikom: Porovnanie dvoch studii]. Casopis Lekaru Ceskych 2004;143(5):324-8. 3032340
61. Bongaerts G, Severijnen R, Timmerman H. Effect of antibiotics, prebiotics and probiotics in treatment for hepatic encephalopathy. Medical Hypotheses 2005;64(1):64-8. 3032344
62. Cabre E, Gassull MA. Nutrition in liver disease. Current Opinion in Clinical Nutrition and Metabolic Care 2005;8(5):545-51. 3032352
63. Cash WJ, McConville P, McDermott E, McCormick PA, Callender ME, McDougall NI. Current concepts in the assessment and treatment of hepatic encephalopathy. QJM : Monthly Journal of the Association of Physicians 2010;103(1):9-16. 3032360
64. Chadalavada R, Sappati Biyyani RS, Maxwell J, Mullen K. Nutrition in hepatic encephalopathy. Nutrition in Clinical Practice 2010;25(3):257-64. 3032362
65. Chauhan SV, Chorawala MR. Probiotics, prebiotics and synbiotics. International Journal of Pharmaceutical Sciences and Research 2012;3:711-26. 3032366
66. Cheung K, Lee SS, Raman M. Prevalence and mechanisms of malnutrition in patients with advanced liver disease, and nutrition management strategies. Clinical Gastroenterology and Hepatology 2012;10:117-25. 3032388
67. Chikhacheva EA, Seliverstov PV, Sitkin SI, Dobritsa VP, Radchenko VG. Tactics for the correction of intestinal microbiocenotic disorders in the combination therapy of patients with chronic liver diseases. Terapevticheskii Arkhiv 2014;86:52-7. 3032392
68. Ciorba MA. A gastroenterologist's guide to probiotics. Clinical Gastroenterology and Hepatology 2012;10:960-8. 3032400
69. Colle R, Ceschia T. Oral bacteriotherapy with Bifidobacterium bifidum and Lactobacillus acidophilus in cirrhotic patients [Batterioterapia orale con Bifidobacterium bifidum e Lactobacillus acidophilus nel cirrotico]. Clinica Terapeutica 1989;131(6):397-402. 3032404
70. Conn HO, Floch MH. Effects of lactulose and Lactobacillus acidophilus on the fecal flora. American Journal of Clinical Nutrition 1970;23(12):1588-94. 3032408
71. Crittenden NE, McClain C. Management of patients with moderate alcoholic liver disease. Clinical Liver Disease 2013;2:76-9. 3032412
72. Dai G, Wu D, Lian J, Ma H, Jiang B. Clinical research on microecologic treatment combined enteral nutrition for hepatic encephalopathy. Zhonghua Liu Xing Bing Xue Za Zhi 2014; Vol. 35, issue 12:1392-5. [0254-6450]3032416
73. Dasarathy S. Role of gut bacteria in the therapy of hepatic encephalopathy with lactulose and antibiotics. Indian Journal of Gastroenterology 2003;22(Suppl 2):S50-3. 3032418
74. Dbouk N, McGuire BM. Hepatic encephalopathy: a review of its pathophysiology and treatment. Current Treatment Options in Gastroenterology 2006;9(6):464-74. 3032420
75. Demeter P. The possibilities of using probiotics in digestive diseases [A probiotikumok alkalmazasanak lehetosegei emesztoszervi betegsegekben]. Lege Artis Medicine 2006;16(1):41-7. 3032424
76. De Micco I, D'Aniello R, Sangermano M, Mandato C, Paolella G, Lenta S, et al. A systematic review of pediatric NAFLD therapy: year 2012. Digestive and Liver Disease 2012; Vol. 44:S288. [1590-8658]3032426
77. Dhiman RK, Chawla YK. Minimal hepatic encephalopathy: should we start treating it?. Gastroenterology 2004;127(6):1855-7. 3032428
78. Dhiman RK. Minimal hepatic encephalopathy: has the time come to recognize and treat it?. Bulletin, Postgraduate Institute of Medical Education and Research, Chandigarh 2007;41(1):1-4. 3032430
79. Dhiman RK, Chawla YK. Minimal hepatic encephalopathy. Indian Journal of Gastroenterology 2009;28(1):5-16. 3032432
80. Dhiman RK, Saraswat VA, Sharma BK, Sarin SK, Chawla YK, Butterworth R, et al. Minimal hepatic encephalopathy: consensus statement of a working party of the Indian National Association for Study of the Liver. Journal of Gastroenterology and Hepatology 2010;25(6):1029-41. 3032434
81. Dhiman RK, Rana BS, Garg A, Khattri A, Chopra M, Thumburu KK, et al. Efficacy and safety of a probiotic preparation in the secondary prophylaxis of hepatic encephalopathy in cirrhotic patients: interim results of a double blind, randomized, placebo controlled study. Hepatology (Baltimore, Md.) 2012; Vol. 56:255A. [0270-9139]3032436
82. Dhiman RK. Gut microbiota and hepatic encephalopathy. Metabolic Brain Disease 2013;28:321-6. 3032438
83. Dhiman RK, Rana B, Agrawal S, Garg A, Chopra M, Thumburu KK, et al. Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial. Gastroenterology 2014; Vol. 147, issue 6:1327-37.e3. 3032440
84. Dhiman RK. Hepatic encephalopathy. Journal of Clinical & Experimental Hepatology 2015; Vol. 5, issue S1:S1-2. [0973-6883]3032442
85. Ding X, Zhang F, Wang Y. Letter: probiotics vs. lactulose for minimal hepatic encephalopathy therapy. Alimentary Pharmacology & Therapeutics 2014;39:1000. 3032450
86. Ding X, Zhang FC, Wang YJ. Probiotics versus lactulose for minimal hepatic encephalopathy therapy: a randomized controlled trial meta-analysis. Journal of Digestive Diseases 2014; Vol. 15:135. [1751-2972]3032452
87. Doron S, Snydman DR, Gorbach SL. Lactobacillus GG: bacteriology and clinical applications. Gastroenterology Clinics of North America 2005;34(3):483-98. 3032456
88. Druart C, Alligier M, Salazar N, Neyrinck AM, Delzenne NM. Modulation of the gut microbiota by nutrients with prebiotic and probiotic properties. Advances in Nutrition 2014; Vol. 5, issue 5:624S-33S. [2161-8313]3032458
89. Dylag K, Hubalewska-Mazgaj M, Surmiak M, Szmyd J, Brzozowski T. Probiotics in the mechanism of protection against gut inflammation and therapy of gastrointestinal disorders. Current Pharmaceutical Design 2014;20:1149-55. 3032460
90. EASL . 47th Annual Meeting of the European Association for the Study of the Liver. Journal of Hepatology 2012;56(Suppl 2):S1-S614. 3032462
91. Eguchi S, Takatsuki M, Hidaka M, Soyama A, Ichikawa T, Kanematsu T. Perioperative synbiotic treatment to prevent infectious complications in patients after elective living donor liver transplantation: a prospective randomized study. American Journal of Surgery 2011;201(4):498-502. 3032466
92. El-Nezami HS, Polychronaki NN, Ma J, Zhu HL, Ling WH, Salminen EK, et al. Probiotic supplementation reduces a biomarker for increased risk of liver cancer in young men from Southern China. American Journal of Clinical Nutrition 2006; Vol. 83, issue 5:1199-203. [0002-9165]3032470
93. Eslamparast T, Poustchi H, Zamani F, Sharafkhah M, Malekzadeh R, Hekmatdoost A. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. American Journal of Clinical Nutrition 2014; Vol. 99, issue 3:535-42. [0002-9165]3032472
94. Fan N, Tian ZB, Kong XJ, Zhao QX, Wei LZ. Bifico improves intestinal macromolecular permeability in patients with liver cirrhosis. World Chinese Journal of Digestology 2009;17(36):3745-8. 3032480
95. Fan JG, Cao HX. Role of diet and nutritional management in non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology 2013;28:81-7. 3032482
96. Fehervari I, Nemes B, Gorog D, Gerlei Z, Kobori L. Hepatic encephalopathy and liver transplantation. Magyar Sebeszet 2012;65:58-62. 3032486
97. Ferenci P. Hepatic encephalopathy [Hepatische enzephalopathie]. Deutsche Medizinische Wochenschrift 2001;126(Suppl 1):S76-80. 3032488
98. Ferenci P. Treatment options for hepatic encephalopathy: a review. Seminars in Liver Disease 2007;27(Suppl 2):10-7. 3032490
99. Feret B, Barner B. Rifaximin: a nonabsorbable, broad-spectrum antibiotic for reduction in the risk for recurrence of overt hepatic encephalopathy. Formulary 2010;45(7):210-6. 3032492
100. Ferreira LG, Anastacio LR, Correia M. The impact of nutrition on cirrhotic patients awaiting liver transplantation. Current Opinion in Clinical Nutrition and Metabolic Care 2010;13(5):554-61. 3032494
101. Festi D, Schiumerini R, Eusebi LH, Marasco G, Taddia M, Colecchia A. Gut microbiota and metabolic syndrome. World Journal of Gastroenterology 2014; Vol. 20, issue 43:16079-94. [1007-9327]3032496
102. Finney M, Smullen J, Foster HA, Brokx S, Storey DM. Effects of low doses of lactitol on faecal microflora, pH, short chain fatty acids and gastrointestinal symptomology. European Journal of Nutrition 2007;46(6):307-14. 3032498
103. Floch MH. Intestinal microbiota metabolism of a prebiotic to treat hepatic encephalopathy. Clinical Gastroenterology and Hepatology 2015; Vol. 13, issue 1:209. [1542-3565]3032502
104. Fontana L, Bermudez-Brito M, Plaza-Diaz J, Munoz-Quezada S, Gil A. Sources, isolation, characterisation and evaluation of probiotics. British Journal of Nutrition 2013;109:S35-50. 3032504
105. Fooladi AAI, Hosseini HM, Nourani MR, Khani S, Alavian SM. Probiotic as a novel treatment strategy against liver disease. Hepatitis Monthly 2013;13(2):e7521. 3032506
106. Foster KJ, Lin S, Turck CJ. Current and emerging strategies for treating hepatic encephalopathy. Critical Care Nursing Clinics of North America 2010;22(3):341-50. 3032508
107. Fujita T. Probiotics for patients with liver cirrhosis. Journal of Hepatology 2008;49(6):1080-1. 3032512
108. Fuster GO, Gonzalez-Molero I. Probiotics and prebiotics in clinical practice. Nutricion Hospitilaria 2007;22:26-34. 3032514
109. Galhenage S, Almeida J, Yu J, Kurtovic J, Segal I, Riordan SM. Modulation of intestinal flora for the treatment of hepatic encephalopathy in cirrhosis. In: Haussinger D, Kircheis G, Schliess F editor(s). Hepatic Encephalopathy and Nitrogen Metabolism. Dordrecht: Springer, 2006:539-50. 3032516
110. Ganguli K, Meng D, Rautava S, Lu L, Walker WA, Nanthakumar N. Probiotics prevent necrotizing enterocolitis by modulating enterocyte genes that regulate innate immune-mediated inflammation. American Journal of Physiology. Gastrointestinal and Liver Physiology 2013; Vol. 304, issue 2:G132-41. [0193-1857]3032518
111. Garcia JJ, Rodero GC, Calanas-Continente A. Importance of nutritional support in patients with hepatic encephalopathy. Nutricion Hospitalaria 2012;27:372-81. 3032520
112. Garcovich M, Zocco MA, Roccarina D, Ponziani FR, Gasbarrini A. Prevention and treatment of hepatic encephalopathy: focusing on gut microbiota. World Journal of Gastroenterology 2012;18:6693-700. 3032524
113. Gareau MG. Microbiota-gut-brain axis and cognitive function. Advances in Experimental Medicine and Biology. Springer New York LLC, 2014; Vol. 817:357-71. [0065-2598]3032526
114. Gluud LL, Dam G, Borre M, Les I, Cordoba J, Marchesini G, et al. Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?. Metabolic Brain Disease 2013;28:221-5. 3032528
115. Gomez-Hurtado I, Such J, Sanz Y, Frances R. Gut microbiota-related complications in cirrhosis. World Journal of Gastroenterology 2014; Vol. 20, issue 42:15624-31. [1007-9327]3032530
116. Grat M, Holowko W, Galecka M, Grat K, Szachta P, Lewandowski Z, et al. Gut microbiota in cirrhotic liver transplant candidates. Hepato-Gastroenterology 2014; Vol. 61, issue 134:1661-7. [0172-6390]3032538
117. Gratz SW, Mykkanen H, El-Nezami HS. Probiotics and gut health: a special focus on liver diseases. World Journal of Gastroenterology 2010;16(4):403-10. 3032540
118. Greco F, Barone G, Gargante MP, Malaguarnera M, Toscano MA. Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Digestive Diseases and Sciences 2007;52(11):3259-65. 3032542
119. Gu L, Yan S, Li D, Wang J, Wang Q. Effect of glutamine combined with probiotics on intestinal mucosal barrier and liver function in patients with liver cirrhosis. Chinese Journal of Gastroenterology 2014; Vol. 19, issue 4:213-6. [1008-7125]3032548
120. Guarner F, Khan AG, Garisch J, Eliakim R, Gangl A, Thomson A, et al. World Gastroenterology Organisation practice guideline: probiotics and prebiotics. Arab Journal of Gastroenterology 2009;10(1):33-42. 3032550
121. Guarner F, Khan AG, Garisch J, Eliakim R, Gangl A, Thomson A, et al. World Gastroenterology Organisation global guidelines: probiotics and prebiotics October 2011. Journal of Clinical Gastroenterology 2012;46:468-81. 3032552
122. Guerrero HI, Torre DA, Vargas VF, Uribe M. Intestinal flora, probiotics, and cirrhosis. Annals of Hepatology 2008;7(2):120-4. 3032554
123. Gupta N, Kumar A, Sharma B, Sarin SK. Addition of probiotics to propranolol improves response for primary prophylaxis of variceal bleeding in patients with cirrhosis and large esophageal varices. Hepatology (Baltimore, Md.) 2010; Vol. 52:1064A. [0270-9139]3032556
124. Gupta N, Sarin SK, Sharma BC, Garg V, Kumar A. Addition of probiotics to propranolol improves response for primary prophylaxis of variceal bleeding in patients with cirrhosis and large esophageal varices. Indian Journal of Gastroenterology 2010; Vol. 1:A45. [0254-8860]3032558
125. Gupta N, Kumar A, Sharma P, Garg V, Sharma BC, Sarin SK. Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial. Liver International 2013; Vol. 33, issue 8:1148-57. [1478-3223]3032560
126. Hellinger WC, Yao JD, Alvarez S, Blair JE, Cawley JJ, Paya CV, et al. A randomized, prospective, double-blinded evaluation of selective bowel decontamination in liver transplantation. Transplantation 2002; Vol. 73, issue 12:1904-9. [0041-1337]3032574
127. Higashikawa F, Noda M, Awaya T, Nomura K, Oku H, Sugiyama M. Improvement of constipation and liver function by plant-derived lactic acid bacteria: a double-blind, randomized trial. Nutrition 2010;26(4):367-74. 3032578
128. Holte K, Krag A, Gluud LL. Systematic review and meta-analysis of randomized trials on probiotics for hepatic encephalopathy. Hepatology Research 2012;42:1008-15. 3032580
129. Hotten P, Marotta F, Naito Y, Minelli E, Helmy A, Lighthouse J, et al. Effects of probiotics, lactitol and rifaximin on intestinal flora and fecal excretion of organic acids in cirrhotic patients. Chinese Journal of Digestive Diseases 2003;4(1):13-8. 3032588
130. Hutt P, Koll P, Stsepetova J, Alvarez B, Mandar R, Krogh-Andersen K, et al. Safety and persistence of orally administered human Lactobacillus sp. strains in healthy adults. Beneficial Microbes 2011;2:79-90. 3032596
131. Ianiro G, Bibbo S, Gasbarrini A, Cammarota G. Therapeutic modulation of gut microbiota: current clinical applications and future perspectives. Current Drug Targets 2014;15:762-70. 3032598
132. Iannitti T, Palmieri B. Therapeutical use of probiotic formulations in clinical practice. Clinical Nutrition 2010;29(6):701-25. 3032600
133. Imler M, Kurtz D, Bockel R, Stahl J. Comparative study of portocaval encephalopathy treatment with lactulose, lactobacilli and antibiotics [Etude comparative du traitement de l'encephalopathie porto-cave par le lactulose, les bacilles lactiques et les antibiotiques]. Therapeutique 1971;47(3):237-48. 3032602
134. Ivanovic N, Minic R, Djuricic I, Dimitrijevic L, Sobajic S, Zivkovic I, et al. Brain and liver fatty acid composition changes upon consumption of Lactobacillus rhamnosus LA68. International Journal of Food Sciences and Nutrition 2015; Vol. 66, issue 1:93-7. [0963-7486]3032606
135. Janczyk W, Socha P. Non-alcoholic fatty liver disease in children. Clinics and Research in Hepatology and Gastroenterology 2012;36:297-300. 3032610
136. Jayakumar S, Tandon P, Bain V, Ma MM, Madsen K, Bailey RJ, et al. Probiotics do not reduce portal pressure in patients with decompensated cirrhosis. Hepatology (Baltimore, Md.) 2012; Vol. 56:744A. [0270-9139]3032612
137. Jayakumar S, Carbonneau M, Hotte N, Befus AD, St. Laurent C, Owen R, et al. VSL#3 probiotic therapy does not reduce portal pressures in patients with decompensated cirrhosis. Liver International 2013; Vol. 33, issue 10:1470-7. [1478-3223]3032614
138. Jeejeebhoy KN. Enteral feeding. Critical Care Medicine 2004;20(2):110-3. 3032616
139. Jiang CY, Wang BE, Chen D. Protective effect of compound tongfu granule on intestinal mucosal barrier in patients with cirrhosis of decompensation stage. Chinese Journal of Integrated Traditional and Western Medicine 2008;28(9):784-7. 3032626
140. Jones C, Badger SA, Regan M, Clements BW, Diamond T, Parks RW, et al. Modulation of gut barrier function in patients with obstructive jaundice using probiotic LP299v. European Journal of Gastroenterology & Hepatology 2013; Vol. 25, issue 12:1424-30. [0954-691X]3032634
141. Jonkers D, Stockbrugger R. Review article: probiotics in gastrointestinal and liver diseases. Alimentary Pharmacology & Therapeutics 2007;26:133-48. 3032636
142. Jover-Cobos M, Khetan V, Jalan R. Treatment of hyperammonemia in liver failure. Current Opinion in Clinical Nutrition and Metabolic Care 2014;17:105-10. 3032638
143. Jun DW, Nam HH, Moon JH, Kim TY, Sohn JH, Koh DH. Randomized clinical trial: Effects of multi-species probiotics on small intestinal bacterial overgrowth in patients with chronic liver disease - a placebo controlled study. Hepatology (Baltimore, Md.) 2013; Vol. 58:867A. [0270-9139]3032640
144. Jurado Garcia J, Costan Rodero G, Calanas-Continente A. Importance of nutritional support in patients with hepatic encephalopathy. Nutricion Hospitalaria 2012; Vol. 27, issue 2:372-81. [0212-1611]3032642
145. Kachaamy T, Bajaj JS. Diet and cognition in chronic liver disease. Current Opinion in Gastroenterology 2011;27(2):174-9. 3032644
146. Kadayifci A, Merriman RB, Bass NM. Medical treatment of non-alcoholic steatohepatitis. Clinics in Liver Disease 2007;11(1):119-40. 3032646
147. Karczewski J, Troost FJ, Konings I, Dekker J, Kleerebezem M, Brummer RJM, et al. Regulation of human epithelial tight junction proteins by Lactobacillus plantarum in vivo and protective effects on the epithelial barrier. American Journal of Physiology. Gastrointestinal and Liver Physiology 2010;298(6):G851-9. 3032650
148. Keeffe EB. Hepatic encephalopathy. Seminars in Liver Disease 2007;27(Suppl 2):1-2. 3032652
149. Khungar V, Poordad F. Hepatic encephalopathy. Clinics in Liver Disease 2012;16:301-20. 3032658
150. Kirpich IA, Solovieva NV, Leikhter SN, Shidakova NA, Lebedeva OV, Sidorov PI, et al. Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol 2008; Vol. 42, issue 8:675-82. 3032666
151. Kitagawa K, Ishikawa H, Oda T, Saito H, Morishita N, Shimamoto K, et al. Development of combination therapy of bifidobacterium-based oral vaccine displaying HCV-NS3 with interferon-alpha. Molecular Therapy 2015; Vol. 23:S259. [1525-0016]3032668
152. Koga H, Tamiya Y, Mitsuyama K, Ishibashi M, Matsumoto S, Imaoka A, et al. Probiotics promote rapid-turnover protein production by restoring gut flora in patients with alcoholic liver cirrhosis. Hepatology International 2013; Vol. 7, issue 2:767-74. [1936-0533]3032670
153. Kremer H. Intestine and liver-protective therapy [Darm- und Leberschutztherapie]. Zeitschrift für Allgemeinmedizin 1974;50(28):1252-5. 3032680
154. Kumashiro R. Treatment of minimal hepatic encephalopathy. Hepatology Research 2008;38(Suppl 1):S128-31. 3032690
155. Kwak DS, Jun DW, Seo JG, Chung WS, Park S-E, Lee KN, et al. Short-term probiotic therapy alleviates small intestinal bacterial overgrowth, but does not improve intestinal permeability in chronic liver disease. European Journal of Gastroenterology & Hepatology 2014; Vol. 26, issue 12:1353-9. [0954-691X]3032692
156. Lata J, Jurankova J, Pribramska V, Fric P, Senkyrik M, Dite P, et al. Effect of administration of Escherichia coli Nissle (Mutaflor) on intestinal colonisation, endo-toxemia, liver function and minimal hepatic encephalopathy in patients with liver cirrhosis [Vliv podani Escherichia coli Nissle (Mutaflor) na strevni osidleni, endotoxemii, funkcni stav jater a minimalni jaterni encefalopatii u nemocnych s jaterni cirhozou]. Vnitrni Lekarstvi 2006;52(3):215-9. 3032698
157. Lata J, Novotny I, Pribramska V, Jurankova J, Fric P, Kroupa R, et al. The effect of probiotics on gut flora, level of endotoxin and Child-Pugh score in cirrhotic patients: results of a double-blind randomized study. European Journal of Gastroenterology & Hepatology 2007;19(12):1111-3. 3032700
158. Lata J, Jurankova J, Fric P, Pribramska V. The effect of probiotics on gut flora, level of endotoxin and Child-Pugh score in cirrhotic patients - Results of double blind randomized study. Gastroenterology 2007; Vol. 132, issue 4:A797-8. [0016-5085]3032702
159. Lata J, Jurankova J, Pribramska V. The effects of probiotics on level of endotoxin in patients with liver disease - potential therapy of non alcoholic steatohepatitis?. Journal of Diabetes 2009;1(Suppl):A150. 3032704
160. Lata J, Jurankova J, Kopacova M, Vitek P. Probiotics in hepatology. World Journal of Gastroenterology 2011;17:2890-6. 3032706
161. Leber B, Spindelboeck W, Stadlbauer V. Infectious complications of acute and chronic liver disease. Seminars in Respiratory & Critical Care Medicine 2012;33:80-95. 3032710
162. Liboredo JC, Abreu Ferrari MDL, Vilela EG, Lima AS, Toulson Davisson Correia MI. The effect of Saccharomyces boulardii in patients eligible for liver transplantation. Nutricion Hospitalaria 2015; Vol. 31, issue 2:778-84. [0212-1611]3032732
163. Lien T-H, Bu L-N, Wu J-F, Chen H-L, Chen A-C, Lai M-W, et al. Use of lactobacillus casei rhamnosus to prevent cholangitis in biliary atresia after Kasai operation. Journal of Pediatric Gastroenterology and Nutrition 2015; Vol. 60, issue 5:654-8. [0277-2116]3032734
164. Lighthouse J, Naito Y, Helmy A, Hotten P, Fuji H, Min CH, et al. Endotoxinemia and benzodiazepine-like substances in compensated cirrhotic patients: a randomized study comparing the effect of rifaximine alone and in association with a symbiotic preparation. Hepatology Research 2004;28(3):155-60. 3032736
165. Liu JS, Tian Y, Fu J, Zhang XH, Liu J, Lin J. Effects of probiotics agents treatment on the course of subclinical hepatic encephalopathy. Chinese Journal of Postgraduates of Medicine 2006; Vol. 29, issue 1C:12-4. 3032740
166. Liu W. Effect of administration of Medilac-S probiotics on endo-toxemia and hepatic encephalopathy. Chinese Medicine of Factory and Mine 2009; Vol. 22, issue 3:296-7. 3032742
167. Liu JE, Zhang Y, Zhang J, Dong PL, Chen M, Duan ZP. Probiotic yogurt effects on intestinal flora of patients with chronic liver disease. Nursing Research 2010;59(6):426-32. 3032744
168. Liu J, Wu D, Ahmed A, Li X, Ma Y, Tang L, et al. Comparison of the gut microbe profiles and numbers between patients with liver cirrhosis and healthy individuals. Current Microbiology 2012;65:7-13. 3032746
169. Llorente C, Schnabl B. The gut microbiota and liver disease. Cellular and Molecular Gastroenterology and Hepatology 2015; Vol. 1, issue 3:275-84. [2352-345X]3032752
170. Loguercio C, De Simone T, Federico A, Terracciano F, Tuccillo C, Di Chicco M, et al. Gut-liver axis: a new point of attack to treat chronic liver damage?. American Journal of Gastroenterology 2002;97(8):2144-6. 3032754
171. Loguercio C, Federico A, Tuccillo C, Terracciano F, D'Auria MV, De Simone C, et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. Journal of Clinical Gastroenterology 2005;39(6):540-3. 3032756
172. Louvet A, Mathurin P. Alcoholic liver disease: Mechanisms of injury and targeted treatment. Nature Reviews. Gastroenterology & Hepatology 2015; Vol. 12, issue 4:231-42. [1759-5045]3032762
173. Lu H, Wu Z, Xu W, Yang J, Chen Y, Li L. Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Intestinal microbiota of HBV cirrhotic patients. Microbial Ecology 2011;61:693-703. 3032764
174. Luna LEM, Fafutis-Morris M, Segura-Ortega JE, Delgado V, Zuniga-Partida V. Prebiotic vs symbiotic to decrease ammonium levels in cirrhotic patients with and without minimal hepatic encephalopathy. Hepatology (Baltimore, Md.) 2010; Vol. 52:919A. [0270-9139]3032766
175. Lunia MK, Sachdeva S, Srivastava S, Sharma BC. An open label randomised controlled trial of probiotics for primary prophylaxis of hepatic encephalopathy in patients with cirrhosis. Journal of Gastroenterology and Hepatology 2012; Vol. 27:241. [0815-9319]3032768
176. Lunia MK, Sharma BC, Sachdeva S, Srivastava S. An open label randomised controlled trial of probiotics for primary prophylaxis of hepatic encephalopathy in patients with cirrhosis. Journal of Hepatology 2013; Vol. 58:S35. [0168-8278]3032770
177. Lunia MK, Sharma BC, Sharma P, Sachdeva S, Srivastava S. Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial. Clinical Gastroenterology and Hepatology 2014; Vol. 12, issue 6:1003-8.e1. [1542-3565]3032771
178. Luo M, Li L, Lu CZ, Cao WK. Clinical efficacy and safety of lactulose for minimal hepatic encephalopathy: a meta-analysis. European Journal of Gastroenterology & Hepatology 2011;23:1250-7. 3032773
179. Ma YY, Li L, Yu CH, Shen Z, Chen LH, Li YM. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World Journal of Gastroenterology 2013;19:6911-8. 3032777
180. Machado MV, Cortez-Pinto H. Gut microbiota and nonalcoholic fatty liver disease. Annals of Hepatology 2012;11:440-9. 3032779
181. Madsen K. Probiotics in critically ill patients. Journal of Clinical Gastroenterology 2008;42(8):S116-8. 3032781
182. Malaguarnera M, Greco F, Barone G, Gargante MP, Malaguarnera M, Toscano MA. Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Digestive Diseases and Sciences 2007; Vol. 52, issue 11:3259-65. [CN-00609431]3032785
183. Malaguarnera M, Vacante M, Antic T, Giordano M, Chisari G, Acquaviva R, et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Digestive Diseases and Sciences 2012; Vol. 57, issue 2:545-53. [0163-2116]3032787
184. Marteau P. Prebiotics and probiotics for gastrointestinal health. Clinical Nutrition 2001;20:41-5. 3032795
185. Marteau P, Bourton-Ruault MC. Nutritional advantages of probiotics and prebiotics. British Journal of Nutrition 2002;87(Suppl 2):S153-7. 3032797
186. Marteu P. Prebiotics and probiotics for gastrointestinal health. Clinical Nutrition 2001;20(Suppl 1):41-5. 3032799
187. Michelfelder AJ, Lee KC, Bading EM. Integrative medicine and gastrointestinal disease. Primary Care - Clinics in Office Practice 2010;37(2):255-67. 3032827
188. Minemura M, Shimizu Y. Gut microbiota and liver diseases. World Journal of Gastroenterology 2015; Vol. 21, issue 6:1691-702. [1007-9327]3032831
189. Mishra SK, Mishra P, Saxena M. Probiotics: an approach for better treatment. Research Journal of Pharmaceutical, Biological and Chemical Sciences 2012;3:1042-61. 3032833
190. Mohammad RA, Regal RE, Alaniz C. Combination therapy for the treatment and prevention of hepatic encephalopathy. Annals of Pharmacotherapy 2012;46:1559-63. 3032843
191. Montagnese S, Amodio P, Angeli P. What type of probiotic was used?. European Journal of Gastroenterology & Hepatology 2012;24:471-2. 3032847
192. Montgomery JY, Bajaj JS. Advances in the evaluation and management of minimal hepatic encephalopathy. Current Gastroenterology Reports 2011;13(1):26-33. 3032849
193. Montrose DC, Floch MH. Probiotics used in human studies. Journal of Clinical Gastroenterology 2005;39(6):469-84. 3032853
194. Moreno-Luna LE, Fafutis-Morris M, Delgado Rizo V, Zuniga V, Segura-Ortega JE. Oral supplementation of symbiotic to decrease ammonium levels in cirrhotic patients with or without minimal hepatic encephalopathy. Hepatology International 2011;5(1):346. 3032861
195. Morgan MY, Blei A, Grungreiff K, Jalan R, Kircheis G, Marchesini G, et al. The treatment of hepatic encephalopathy. Metabolic Brain Disease 2007;22(3-4):389-405. 3032863
196. Mullen KD, Ferenci P, Bass NM, Leevy CB, Keeffe EB. An algorithm for the management of hepatic encephalopathy. Seminars in Liver Disease 2007;27(Suppl 2):32-47. 3032865
197. Nabavi S, Rafraf M, Somi MH, Homayouni-Rad A, Asghari-Jafarabadi M. Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease. Journal of Dairy Science 2014; Vol. 97, issue 12:7386-93. [0022-0302]3032871
198. Nazir S, Lau K, Sindram D, Martinie J, Asarian A, Iannitti D. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open label, randomized controlled trial of lactulose, probiotics and no-therapy. American Congress of Gastroenterology 2010;105:282. 3032875
199. NCT01135628 . Hyperproteic and fiber-rich diet plus probiotics (lactobacillus reuteri) and nitazoxanide in the treatment of minimal hepatic encephalopathy. clinicaltrials.gov/ct2/show/NCT01135628 (first received 26 May 2010). 3033153
200. Olveira Fuster G, Gonzalez-Molero I. Probiotics and prebiotics in clinical practice. Nutricion Hospitalaria 2007; Vol. 22:26-34. [0212-1611]3032897
201. Oshea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. American Journal of Gastroenterology 2010;105(1):14-32. 3032901
202. Pande C, Kumar A, Sarin SK. Addition of probiotics to antibiotics does not improve its efficacy in prevention of spontaneous bacterial peritonitis: a double blind placebo-controlled randomized controlled trial. Hepatology (Baltimore, Md.) 2009;50(4 Suppl):454A. 3032907
203. Pande C, Kumar A, Sarin SK. Addition of probiotics to norfloxacin does not improve efficacy in the prevention of spontaneous bacterial peritonitis: A double-blind placebo-controlled randomized-controlled trial. European Journal of Gastroenterology & Hepatology 2012; Vol. 24, issue 7:831-9. [0954-691X]3032909
204. Paolella G, Mandato C, Pierri L, Poeta M, Di Stasi M, Vajro P. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease. World Journal of Gastroenterology 2014; Vol. 20, issue 42:15518-31. [1007-9327]3032911
205. Park J, Floch MH. Prebiotics, probiotics, and dietary fiber in gastrointestinal disease. Gastroenterology Clinics of North America 2007;36(1):47-63. 3032913
206. Patel R, Dupont HL. New approaches for bacteriotherapy: prebiotics, new-generation probiotics, and synbiotics. Clinical Infectious Diseases 2015; Vol. 60:S108-21. [1058-4838]3032921
207. Pawar R, Pardeshi M, Ghongane B. Study of effects of probiotic lactobacilli in preventing major complications in patients of liver cirrhosis. International Journal of Research in Pharmaceutical and Biomedical Sciences 2012; Vol. 3, issue 1:206-11. 3032923
208. Phongsamran PV, Kim JW, Cupo Abbott J, Rosenblatt A. Pharmacotherapy for hepatic encephalopathy. Drugs 2010;70(9):1131-48. 3032927
209. Plaza-Diaz J, Gomez-Llorente C, Abadia-Molina F, Saez-Lara MJ, Campana-Martin L, Munoz-Quezada S, et al. Effects of Lactobacillus paracasei CNCM I-4034, Bifidobacterium breve CNCM I-4035 and Lactobacillus rhamnosus CNCM I-4036 on hepatic steatosis in zucker rats. PLoS ONE 2014; Vol. 9, issue 5:9. [1932-6203]3032933
210. Poh Z, Chang PEJ. A current review of the diagnostic and treatment strategies of hepatic encephalopathy. International Journal of Hepatology 2012;2012:480309. 3032935
211. Poustchi H, Eslamparast T, Zamani F, Sharafkhah M, Eghtesad S, Malekzadeh R, et al. Effects of synbiotic supplementation on nonalcoholic fatty liver disease. Journal of Gastroenterology and Hepatology 2013; Vol. 28:850-1. [0815-9319]3032939
212. Prakash RK, Kanna S, Mullen KD. Evolving concepts: the negative effect of minimal hepatic encephalopathy and role for prophylaxis in patients with cirrhosis. Clinical Therapeutics 2013;35:1458. 3032943
213. Quigley EMM, Quera R. Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics. Gastroentrology 2006;130(2):S78-90. 3032947
214. Quigley EMM, Stanton C, Murphy EF. The gut microbiota and the liver. Pathophysiological and clinical implications. Journal of Hepatology 2013;58:1020-7. 3032951
215. Quigley EMM. Commentary: Probing probiotics in cirrhosis - A template for future studies?. Alimentary Pharmacology & Therapeutics 2014;39:1334-5. 3032953
216. Quigley EMM, Shanahan F. The future of probiotics for disorders of the brain-gut axis. Advances in Experimental Medicine and Biology 2014;817:417-32. [978-1-4939-0896-7; 978-1-4939-0897-4]3032955
217. Rahimi RS, Rockey DC. Complications of cirrhosis. Current Opinion in Gastroenterology 2012;28:223-9. 3032959
218. Rahimi RS, Rockey DC. End-stage liver disease complications. Current Opinion in Gastroenterology 2013;29:257-63. 3032961
219. Rayes N, Brammer M, Hansen S, Mueller AR, Serke S, Seehofer D, et al. Early enteral supply of lactobacilli and fibre versus SBD - A prospective randomised trial in liver transplant recipients. Journal of Hepatology 2001; Vol. 34:199. [0168-8278]3032971
220. Rayes N, Seehofer D, Hansen S, Boucsein K, Muller AR, Serke S, et al. Early enteral supply of Lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients. Transplantation 2002;74(1):123-8. 3032973
221. Rayes N, Seehofer D, Theruvath T, Schiller RA, Langrehr JM, Jonas S, et al. Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation - A randomized, double-blind trial. American Journal of Transplantation 2005; Vol. 5, issue 1:125-30. [1600-6135]3032977
222. Rayes N, Pilarski T, Stockmann M, Bengmark S, Neuhaus P, Seehofer D. Effect of pre- and probiotics on liver regeneration after resection: a randomised, double-blind pilot study. Beneficial Microbes 2012; Vol. 3, issue 3:237-44. 3032983
223. Read AE, McCarthy CF, Heaton KW, Laidlaw J. Lactobacillus acidophilus (Enpac) in treatment of hepatic encephalopathy. British Medical Journal 1966;1(5498):1267-9. 3032985
224. Reddy VS, Patole SK, Rao S. Role of probiotics in short bowel syndrome in infants and children - a systematic review. Nutrients 2013;5:679-99. 3032987
225. Rifatbegovic Z, Mesic D, Ljuca F, Zildzic M, Avdagic M, Grbic K, et al. Effect of probiotics on liver function after surgery resection for malignancy in the liver cirrhotic. Medicinski Arhiv 2010; Vol. 64, issue 4:208-11. 3032995
226. Riggio O, Ridola L. Emerging drugs for hepatic encephalopathy. Expert Opinion on Emerging Drugs 2009;14(3):537-49. 3032999
227. Rincon D, Vaquero J, Hernando A, Galindo E, Ripoll C, Puerto M, et al. Oral probiotic VSL#3 attenuates the circulatory disturbances of patients with cirrhosis and ascites. Liver International 2014; Vol. 34, issue 10:1504-12. [1478-3223]3033001
228. Riordan SM, Skinner NA, McIver CJ, Liu Q, Bengmark S, Bihari D, et al. Synbiotic-associated improvement in liver function in cirrhotic patients: relation to changes in circulating cytokine messenger RNA and protein levels. Microbial Ecology in Health and Disease 2007;19(1):7-16. 3033005
229. Riordan SM, Williams R. Gut flora and hepatic encephalopathy in patients with cirrhosis. New England Journal of Medicine 2010;362(12):1140-2. 3033007
230. Rivkin A, Gim S. Rifaximin: new therapeutic indication and future directions. Clinical Therapeutics 2011;33:812-27. 3033009
231. Romero-Gomez M. Pharmacotherapy of hepatic encephalopathy in cirrhosis. Expert Opinion on Pharmacotherapy 2010;11(8):1317-27. 3033013
232. Sanchez E, Nieto JC, Boullosa A, Vidal S, Sancho FJ, Rossi G, et al. VSL#3 probiotic treatment decreases bacterial translocation in rats with carbon tetrachloride-induced cirrhosis. Liver International 2015; Vol. 35, issue 3:735-45. [1478-3223]3033019
233. Scevola D, Zambelli A, Concia E, Perversi L, Candiani C. Lactitol and neomycin: monotherapy or combined therapy in the prevention and treatment of hepatic encephalopathy? [Lattitolo e neomicina: monoterapia o terapia combinata nella prevenzione e nel trattamento dell'encefalopatia epatica?]. Clinica Terapeutica 1989;129(2):105-11. 3033023
234. Schiano TD. Treatment options for hepatic encephalopathy. Pharmacotherapy 2010;30(5 pt 2):16S-21S. 3033025
235. Schuster-Wolff-Bühring R, Fischer L, Hinrichs J. Production and physiological action of the disaccharide lactulose. International Dairy Journal 2010; Vol. 20, issue 11:731-41. [0958-6946]3033027
236. Schuster-Wolff-Bühring R, Fischer L, Hinrichs J. Production and physiological action of the disaccharide lactulose. International Dairy Journal 2010;20:731-41. 3033029
237. Segura-Ortega JE, Moreno-Luna LE, Delgado V, Zuniga-Partida V, Fafutis-Morris M. Decrease in ammonium levels and increase in the neutrophils phagocytic capacity in cirrhotic patients after the ingestion of agave inulin and a probiotic mixture of bifidobacterias and lactobillus. Hepatology (Baltimore, Md.) 2010; Vol. 52:917A. [0270-9139]3033035
238. Shang XJ. Effect of treatment with compound Lactobacillus acidophilus on complements and T lymphocyte subsets in patients with compensated liver cirrhosis. World Chinese Journal of Digestology 2013; Vol. 21, issue 24:2446-50. [1009-3079]3033043
239. Sharma BC. Minimal hepatic encephalopathy. Hepatology International 2010; Vol. 4, issue 1:46. [1936-0533]3033049
240. Sharma P, Sharma BC, Agrawal A, Sarin SK. Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labelled randomized controlled trial of lactulose versus no lactulose. Journal of Gastroenterology and Hepatology 2012;27:1329-35. 3033051
241. Sharma P, Sharma BC. Disaccharides in the treatment of hepatic encephalopathy. Metabolic Brain Disease 2013;28:313-20. 3033053
242. Sharma M, Bhat S, Dutt K, Sharma P, Bhat JA. Randomized controlled trial of lactulose and lactulose plus probiotics in the treatment of minimal hepatic encephalopathy. Journal of Evidence Based Medicine and Healthcare 2014; Vol. 1, issue 9:1125-36. 3033055
243. Sharma P, Sharma BC. A survey of patterns of practice and perception of minimal hepatic encephalopathy: a nationwide survey in India. Saudi Journal of Gastroenterology 2014; Vol. 20, issue 5:304-8. [1319-3767]3033057
244. Sharma BC, Maharshi S. Prevention of hepatic encephalopathy recurrence. Clinical Liver Disease 2015; Vol. 5, issue 3:64-7. [2046-2484]3033059
245. Shawcross D, Jalan R. Dispelling myths in the treatment of hepatic encephalopathy. Lancet 2005;365(9457):431-3. 3033061
246. Shen Z, Ma L, Zhang W, Gao S. Curative effect observation of lactobacillus acidophilus complex combined fiberform in treatment of hepatic encephalopathy. Chinese Journal of Microecology 2013; Vol. 25:679-81. 3033065
247. Shen Z, Ma L, Zhang WH. Effects of micro-ecological agents on intestinal flora and blood ammonia of patients with hepatic encephalopathy. Chinese Journal of Nosocomiology 2014;10:2505-7. 3033067
248. Sheth AA, Garcia-Tsao G. Probiotics and liver disease. Journal of Clinical Gastroenterology 2008;42(6):S80-4. 3033069
249. Shu M, Che YG. Curative effects of bacillus licheniformis capsule on course of subclinical hepatic encephalopathy. Chinese Journal of General Practice 2008; Vol. 16:1119-20. 3033075
250. Shukla S, Leisner E, Guha S, Mehboob S. Effects of use of probiotics in minimal hepatic encephalopathy: a meta-analysis of randomized controlled trials. American Journal of Gastroenterology 2009;104:385. 3033077
251. Shukla S, Sampath PK, Shukla A, Guha S, Mehboob S. Comparison of probiotics and lactulose as treatment options in hepatic encephalopathy: a meta-analysis. Gastroenterology 2010;1:S818. 3033079
252. Shukla S, Sampath PK, Shukla A, Guha S, Mehboob S. Use of prebiotics, probiotics and synbiotics in treatment of minimal hepatic encephalopathy: a meta-analysis. Gastroenterology 2010;1:S777. 3033081
253. Shukla S, Shukla A, Mehboob S, Guha S. Meta-analysis: the effects of gut flora modulation using prebiotics, probiotics and synbiotics on minimal hepatic encephalopathy. Alimentary Pharmacology & Therapeutics 2011;33(6):662-71. 3033083
254. Solga SF. Probiotics can treat hepatic encephalopathy. Medical Hypotheses 2003;61(2):307-13. 3033091
255. Soriano G, Guarner C. Probiotics in cirrhosis: do we expect too much?. Liver International 2013;33:1451-3. 3033095
256. Soriano G, Sanchez E, Guarner C. Probiotics in liver diseases. Nutricion Hospitalaria 2013;28:558-63. 3033097
257. Stadlbauer V, Mookerjee RP, Hodges S, Wright GAK, Davies NA, Jalan R. Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. Journal of Hepatology 2008;48(6):945-51. 3033103
258. Stewart CA, Smith GE. Minimal hepatic encephalopathy. Nature Clinical Practice. Gastroenterology & Hepatology 2007;4(12):677-85. 3033109
259. Strasser SI, Vidot H. Nutritional considerations in end-stage liver disease. Journal of Gastroenterology and Hepatology 2011;26:1346-8. 3033113
260. Suk KT, Sohn KM, Kim YD, Cheon GJ, Choi DH, Kim MY, et al. Effect of probiotics (cultured lactobacillus subtilis/streptococcus faecium) in the treatment of alcoholic hepatitis: randomized controlled multicenter study. Hepatology (Baltimore, Md.) 2012; Vol. 56:590A. [0270-9139]3033119
261. Sundaram V, Shaikh OS. Hepatic encephalopathy: pathophysiology and emerging therapies. Medical Clinics of North America 2009;93(4):819-36. 3033123
262. Tang SH, Wang KJ, Wu XJ, Zhang MM. Efficacy of probiotics in the treatment of minimal hepatic encephalopathy: a meta analysis. World Chinese Journal of Digestology 2011;19:2587-92. 3033133
263. Tapper EB, Jiang G, Patwardhan VR. Refining the ammonia hypothesis: a physiology-driven approach to the treatment of hepatic encephalopathy. Mayo Clinic Proceedings 2015; Vol. 90, issue 5:646-58. [0025-6196]3033135
264. Tarantino G, Finelli C. Systematic review on intervention with prebiotics/probiotics in patients with obesity-related nonalcoholic fatty liver disease. Future Microbiology 2015; Vol. 10, issue 5:889-902. [1746-0913]3033137
265. Tarao K, Tamai S, Ito Y, Okawa S, Hayashi M. Effects of lactitol on fecal bacterial flora in patients with liver cirrhosis and hepatic encephalopathy. Nippon Shokakibyo Gakkai Zasshi 1995;92(7):1037-50. 3033139
266. Tojo R, Suarez A, Clemente MG, de los Reyes-Gavilan CG, Margolles A, Gueimonde M, et al. Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis. World Journal of Gastroenterology 2014; Vol. 20, issue 41:15163-76. [1007-9327]3033147
267. Toris GT, Bikis CN, Tsourouflis GS, Theocharis SE. Hepatic encephalopathy: an updated approach from pathogenesis to treatment. Medical Science Monitor 2011;17(2):RA53-63. 3033151
268. Tsochatzis EA, Bosch J, Burroughs AK. New therapeutic paradigm for patients with cirrhosis. Hepatology (Baltimore, Md.) 2012;56:1983-92. 3033155
269. Tsochatzis EA, Bosch J, Burroughs AK. Future treatments of cirrhosis. Expert Review of Gastroenterology & Hepatology 2014;8:571-81. 3033157
270. Upadhyay N, Moudgal V. Probiotics: a review. Journal of Clinical Outcomes Management 2012;19:76-84. 3033161
271. Usami M, Miyoshi M, Kanbara Y, Aoyama M, Sakaki H, Shuno K, et al. Effects of perioperative synbiotic treatment on infectious complications, intestinal integrity, and fecal flora and organic acids in hepatic surgery with or without cirrhosis. Journal of Parenteral and Enteral Nutrition 2011; Vol. 35, issue 3:317-28. [0148-6071]3033163
272. Valentini L, Pinto A, Bourdel-Marchasson I, Ostan R, Brigidi P, Turroni S, et al. Impact of personalized diet and probiotic supplementation on inflammation, nutritional parameters and intestinal microbiota - The "RISTOMED project": Randomized controlled trial in healthy older people. Clinical Nutrition 2015; Vol. 34, issue 4:593-602. [0261-5614]3033173
273. Videhult FK, Ohlund I, Stenlund H, Hernell O, West CE. Probiotics during weaning: a follow-up study on effects on body composition and metabolic markers at school age. European Journal of Nutrition 2015; Vol. 54, issue 3:355-63. [1436-6207]3033187
274. Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology (Baltimore, Md.) 2014;60:715-35. 3033189
275. Vilstrup H, Amodio P, Bajaj J, Ferenci P, Mullen KD, Weissenborn K, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. Journal of Hepatology 2014; Vol. 61, issue 3:642-59. [0168-8278]3033191
276. Vyas U, Ranganathan N. Probiotics, prebiotics, and synbiotics: gut and beyond. Gastroenterology Research and Practice 2012;2012:872716. 3033203
277. Waghray A, Waghray N, Kanna S, Mullen K. Optimal treatment of hepatic encephalopathy. Minerva Gastroenterologica e Dietologica 2014;60:55-70. 3033205
278. Waghray A, Waghray N, Mullen K. Management of covert hepatic encephalopathy. Journal of Clinical and Experimental Hepatology 2015; Vol. 5, issue S1:S75-81. [0973-6883]3033207
279. Wang XY, Qu CM, Liang SW, Cao YJ, Li LY, Zhong CQ, et al. Efficacy analysis on treatment of subclinical hepatic encephalopathy by live combined bacillus subtilis and enterococcus faecium enteric-coated capsules. Progress in Modern Biomedicine 2012; Vol. 12:6489-91. 3033213
280. Wang WF, Cao JB, Xiong JH, Guo HB, Ma L, Chen LQ. Effect of probiotics in improvement of minimal hepatic encephalopathy in cirrhosis patients with hepatitis B virus. Medical & Pharmaceutical Journal of Chinese People's Liberation Army 2015;2:17-20. 3033217
281. Welliver M. Improving treatments for hepatic encephalopathy. Gastroenterology Nursing 2012;35:291-2. 3033221
282. Wong VWS, Wong GLH, Chim AML, Chu WCW, Yeung DKW, Li KCT, et al. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Annals of Hepatology 2013; Vol. 12, issue 2:256-62. [1665-2681]3033235
283. Woo GA, O'Brien C. Long-term management of alcoholic liver disease. Clinics in Liver Disease 2012;16:763-81. 3033237
284. Wright G, Jalan R. Management of hepatic encephalopathy in patients with cirrhosis. Best Practice and Research in Clinical Gastroenterology 2007;21(1):95-110. 3033239
285. Wu WC, Zhao W, Li S. Small intestinal bacteria overgrowth decreases small intestinal motility in the NASH rats. World Journal of Gastroenterology 2008;14(2):313-7. 3033241
286. Xu M, Wang B, Fu Y, Chen Y, Yang F, Lu H, et al. Changes of fecal Bifidobacterium species in adult patients with hepatitis B virus-induced chronic liver disease. Microbial Ecology 2012;63:304-13. 3033251
287. Xu J, Ma R, Chen L-F, Zhao L-J, Chen K, Zhang R-B. Effects of probiotic therapy on hepatic encephalopathy in patients with liver cirrhosis: an updated meta-analysis of six randomized controlled trials. Hepatobiliary & Pancreatic Diseases International 2014;13:354-60. 3033255
288. Xu M, Chang B, Mathews S, Gao B. New drug targets for alcoholic liver disease. Hepatology International 2014; Vol. 8, issue 2:475-80. [1936-0533]3033257
289. Yakabe T, Moore EL, Yokota S, Sui H, Nobuta Y, Fukao M, et al. Safety assessment of Lactobacillus brevis KB290 as a probiotic strain. Food and Chemical Toxicology 2009;47(10):2450-3. 3033259
290. Yao XM, Qu JG, Lin AB, Li HW. Effect of probiotics on non-alcoholic fatty liver disease. Journal of International Pharmaceutical Research 2014; Vol. 41, issue 5:548-51. [1674-0440]3033263
291. Yasutake K, Kohjima M, Nakashima M, Kotoh K, Nakamuta M, Enjoji M. Nutrition therapy for liver diseases based on the status of nutritional intake. Gastroenterology Research and Practice 2012;2012:859697. 3033265
292. Zafirova Z, O'Connor M. Hepatic encephalopathy: current management strategies and treatment, including management and monitoring of cerebral edema and intracranial hypertension in fulminant hepatic failure. Current Opinion in Anaesthesiology 2010;23(2):121-7. 3033275
293. Zamberlin S, Spehar ID, Kelava N, Samarzija D. Probiotic bacterium Lactobacillus rhamnosus: beneficial and adverse effects on human health. Milchwissenschaft - Milk Science International 2012;67:30-3. 3033277
294. Zhang M, Fang T, Zhang J, Yu C. Efficacy of probiotics in treating liver cirrhosis: a meta analysis. Chinese Journal of Gastroenterology 2014;19:25-31. 3033283
295. Zhao HY, Wang HJ, Lu Z, Xu SZ. Intestinal microflora in patients with liver cirrhosis. Chinese Journal of Digestive Diseases 2004;5(2):64-7. 3033285
296. Zucker D, Redulla R. Optimal medical management of minimal hepatic encephalopathy: a systematic review protocol. JBI Database of Systematic Reviews and Implementation Reports 2014;12(6):49-59. [2202-4433]3033289
297. ACTRN12610001021066 . The effects of synbiotics, branched chain amino acids on hepatic encephalopathy. apps.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12610001021066 (irst recieved 22 November 2010). 3033295
298. IRCT201211012417N9 . Effects of probiotics on the level of consciousness in patients with hepatic encephalopathy. apps.who.int/trialsearch/Trial2.aspx?TrialID=IRCT201211012417N9 (first received 24 November 2012). 3033297
299. NCT01798329 . Minimal hepatic encephalopathy in childhood and young adult: epidemiological study and pilot interventional study. clinicaltrials.gov/ct2/show/NCT01798329 (first recieved 19 February 2013). 3033293
300. Allampati S, Mullen KD. Nomenclature and definition of hepatic encephalopathy - An update. Clinical Liver Disease 2015; Vol. 5, issue 3:68-70. [2046-2484]
301. Als-Nielsen B, Koretz RL, Gluud LL, Gluud C. Branched-chain amino acids for hepatic encephalopathy. Cochrane Database of Systematic Reviews 2003, Issue 1. [DOI: 10.1002/14651858.CD001939]
302. Als-Nielsen B, Gluud LL, Gluud C. Benzodiazepine receptor antagonists for hepatic encephalopathy. Cochrane Database of Systematic Reviews 2004, Issue 2. [DOI: 10.1002/14651858.CD002798.pub2]
303. Als-Nielsen B, Gluud LL, Gluud C. Nonabsorbable disaccharides for hepatic encephalopathy. Cochrane Database of Systematic Reviews 2004, Issue 2. [DOI: 10.1002/14651858.CD003044.pub2]
304. Als-Nielsen B, Gluud LL, Gluud C. Dopaminergic agonists for hepatic encephalopathy. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858.CD003047.pub2]
305. Altman DG, Bland JM. Comparing several groups using analysis of variance. BMJ (Clinical Research Ed.) 1996;312:1472-3.
306. Arguedas MR, DeLawrence TG, McGuire BM. Influence of hepatic encephalopathy on health-related quality of life in patients with cirrhosis. Digestive Diseases and Sciences 2003;48:1622-6.
307. Bajaj JS, Cordoba J, Mullen KD, Amodio P, Shawcross DL, Butterworth RF, et al. Review article: the design of clinical trials in hepatic encephalopathy - an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Alimentary Pharmacology & Therapeutics 2011;33(7):739-47.
308. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, et al. Rifaximin treatment in hepatic encephalopathy. New England Journal of Medicine 2010; Vol. 362, issue 12:1071-81. [0028-4793]
309. Besselink MGH, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008;371(9613):651-9.
310. Blei AT, Córdoba J. Hepatic encephalopathy. American Journal of Gastroenterology 2001;96:1968-76.
311. Brazier JE, Harper R, Jones NMB, O'Cathain A, Thomas KJ, Usherwood T, et al. Validating the SF-36® Health Survey Questionnaire: new outcome measure for primary care. BMJ (Clinical Research Ed.) 1992;305:160-4.
312. Butterworth RF, Giguère JF, Michaud J, Lavoie J, Layrargues GP. Ammonia: key factor in the pathogenesis of hepatic encephalopathy. Molecular and Chemical Neuropathology 1987;6:1-12.
313. Conn H, Leevy C, Vlahcevic Z, Rodgers J, Maddrey W, Seeff L, et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology 1977; Vol. 72, issue 4 (Pt 1):573-83. [0016-5085]
314. De Preter V, Vanhoutte T, Huys G, Swings J, Rutgeerts P, Verbeke K. Effect of lactulose and Saccharomyces boulardii administration on the colonic urea-nitrogen metabolism and the bifidobacteria concentration in healthy human subjects. Alimentary Pharmacology & Therapeutics 2006; Vol. 23, issue 7:963-74. [0269-2813: (Print)]
315. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy - Definition, nomenclature, diagnosis, and quantification: final report of the Working Party at the 11th World Congress of Gastroenterology, Vienna, 1998. Hepatology (Baltimore, Md.) 2002;35:716-21.
316. Gluud LL, Dam G, Les I, Córdoba J, Marchesini G, Borre M, et al. Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Database of Systematic Reviews 2015, Issue 9. [DOI: 10.1002/14651858.CD001939.pub3]
317. Gluud C, Nikolova D, Klingenberg SL. Cochrane Hepato-Biliary Group. About Cochrane (Cochrane Review Groups (CRGs)) 2016, Issue 5. Art. No.: LIVER.
318. Brozek J, Oxman A, Schünemann H. GRADEpro. Version 3.2 for Windows. Grade Working Group 2004-2007, 2008.
319. Groeneweg M, Quero JC, De Bruijn I, Hartmann IJC, Essink-bot M, Hop WCJ, et al. Subclinical hepatic encephalopathy impairs daily functioning. Hepatology (Baltimore, Md.) 1998;28:45-9.
320. Higgins JP, Green S, editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
321. International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR & ICH Guidelines. Vol. 1, Philadelphia (PA): Barnett International/PAREXEL, 1997.
322. Jiang Q, Jiang XH, Zheng MH, Chen YP. l ornithine l aspartate in the management of hepatic encephalopathy: a meta analysis. Journal of Gastroenterology and Hepatology 2009;24(1):9-14.
323. Junker AE, Als-Nielsen B, Gluud C, Gluud LL. Dopamine agents for hepatic encephalopathy. Cochrane Database of Systematic Reviews 2014, Issue 2. [DOI: 10.1002/14651858.CD003047.pub3]
324. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9.
325. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
326. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.MR000033.pub2]
327. McGee R, O'Connor PM, Russell D, Dempsey EM, Ryan AC, Ross PR, et al. Prolonged faecal excretion following a single dose of probiotic in low birth weight infants. Acta Paediatrica 2010;99(10):1587-8.
328. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352:609-13.
329. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
330. Riordan SM, Williams R. Treatment of hepatic encephalopathy. New England Journal of Medicine 1997;337:473.
331. Rolfe RD. The role of probiotic cultures in the control of gastrointestinal health. Journal of Nutrition 2000;130:396.
332. Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591-603.
333. Saab S, Suraweera D, Au J, Saab EG, Alper TS, Tong MJ. Probiotics are helpful in hepatic encephalopathy: a meta-analysis of randomized trials. Liver International 2015 Nov 12 [Epub ahead of print]. [1478-3231]
334. Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Health Technology Assessment 2012;16(35):1-82.
335. Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine 2012;157(6):429-38.
336. Schrezenmeir J, de Vrese M. Probiotics, prebiotics, and synbiotics - approaching a definition. American Journal of Clinical Nutrition 2001;73:361S.
337. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
338. Sharon SLW, Wilczynski NL, Haynes RB. Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE. Journal of the Medical Library Association 2006;94:41-7.
339. Shukla S, Shukla A, Mehboob S, Guha S. Meta analysis: the effects of gut flora modulation using prebiotics, probiotics and synbiotics on minimal hepatic encephalopathy. Alimentary Pharmacology & Therapeutics 2011;33:662-71.
340. Stepanova M, Mishra A, Venkatesan C, Younossi ZM. In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009. Clinical Gastroenterology and Hepatology 2012; Vol. 10, issue 9:1034-41.e1. [1542-3565]
341. Stinton LM, Jayakumar S. Minimal hepatic encephalopathy. Canadian Journal of Gastroenterology 2013;27(10):572-4. [0835-7900]
342. Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for Trial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed 13 June 2016).
343. Copenhagen Trial Unit. TSA - Trial Sequential Analysis. Version 0.9 Beta. Copenhagen: Copenhagen Trial Unit, 2011.
344. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The human microbiome project. Nature 2007;449(7164):804-10.
345. Vaquero J, Chung C, Cahill ME, Blei AT. Pathogenesis of hepatic encephalopathy in acute liver failure. Seminars in Liver Disease 2003;23:259-69.
346. Ware JE, Kosinski M, Keller SK. SF-36® Physical and Mental Health Summary Scales: A User's Manual. Boston: The Health Institute, 1994.
347. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008; Vol. 61, issue 1:64-75. [0895-4356]
348. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research Ed.) 2008;336:601-5.
349. Zhao LN, Yu T, Lan SY, Hou JT, Zhang ZZ, Wang SS, et al. Probiotics can improve the clinical outcomes of hepatic encephalopathy: An update meta-analysis. Clinics and Research in Hepatology and Gastroenterology 2015; Vol. 39, issue 6:674-82. [2210-7401]
350. McGee RG, Bakens A, Wiley K, Riordan SM, Webster AC. Probiotics for patients with hepatic encephalopathy. Cochrane Database of Systematic Reviews 2011, Issue 11. [DOI: 10.1002/14651858.CD008716.pub2; 1361-6137]